Current stock page

Stock Analysis

Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Analysis

Rapport Therapeutics, Inc. Common Stock (RAPP) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

RAPP Stock Analysis Summary

Rapport Therapeutics, Inc. Common Stock (RAPP) currently has an AIQ Score of 43/100, indicating a bearish setup. Quality is the strongest factor at 57/100. Momentum is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

RAPP at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$26.15
AIQ Score43/100
Overall ViewBearish
Technical Analysis ConsensusSell
Market Cap$1.25B
P/E Ratio (TTM)-8.25
Forward P/E—
EPS (Q3 FY2026)-$0.84
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.27
Volume316.12K
52-week range$22.06-$52.93
RSI 1444.91
50-Day SMA$31.93
200-Day SMA$35.59
Analyst Price Target$71.63
Next EarningsMar 9, 2027
As of Nov 13, 2026 · Market close

RAPPRapport Therapeutics, Inc. Common Stock

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 3/10
$26.15+$0.30 (+1.16%)

Latest quote

  • Momentum
    33
  • Value
    42
  • Quality
    57
  • Risk resilience
    39
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

RAPP Stock Analysis Summary

Rapport Therapeutics, Inc. Common Stock (RAPP) currently has an AIQ Score of 43/100, indicating a bearish setup. Quality is the strongest factor at 57/100. Momentum is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, RAPP has AIQ Score of 43/100 with Quality base of 57/100 and fading Momentum at 33/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (57/100) leads while Momentum (33/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.16% stock move · RAPP classified in Biotechnology.

Current Evidence

BearishRAPP is in a bearish AIQ regime; Quality is the strongest visible factor at 57/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is RAPP Bullish or Bearish Right Now?

RAPP currently has a bearish overall setup. Quality is the strongest factor at 57/100, while Momentum is weakest at 33/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +173.90% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 42/100.
  • - Momentum is weak at 33/100.
  • - Risk Resilience is weak at 39/100.
  • - Price is -26.52% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (24 vs 15).

Current Consensus

RAPP's Technical Analysis Consensus is currently Sell, with 15 buy, 7 neutral, and 24 sell votes. RAPP's 14-day RSI is 44.91, which places the stock in a weaker momentum range. RAPP's beta is 1.27, indicating greater market sensitivity than the broad market.

Signal Confidence
Moderate agreement

What Changed in RAPP?

The largest recent change in RAPP is AIQ Score moving up by 1.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+1.0
Momentum
+0.0
Quality
+1.0
Risk
+0.0

What Would Change the RAPP Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

RAPP Decision Framework

Public evidence layers, setup checks, and risk context for Rapport Therapeutics, Inc. Common Stock.

Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Analysis

Rapport Therapeutics, Inc. Common Stock has an AIQ Score of 43/100 in a Bearish regime. Quality is strongest at 57/100. Beta is 1.27, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextRAPP is in a Bearish AIQ regime with score 43/100.
Signal ConflictThe primary conflict is that quality leads at 57/100 while momentum lags at 33/100.
Factor EvidenceMomentum 33/100 · Value 42/100 · Quality 57/100 · Risk 39/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Quality is the strongest factor at 57/100.

TimingFail

Momentum is 33/100 and RSI (14) is 44.9.

Regime fitFail

RAPP is in a Bearish regime at 43/100.

Risk controlFail

Risk factor is 39/100 with beta 1.27 and annual volatility 62.34%.

ConflictWait

Current conflict: quality leads at 57/100 while momentum lags at 33/100.

AIQ Score
43/100
Price
$26.15
Beta
1.27
RSI (14)
44.9

RAPP Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

RAPP Fundamentals

RAPP valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$40.24M
Free cash flow
-$41.63M
View full RAPP fundamental analysis

RAPP Technical Analysis

RAPP technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
44.91
Price vs SMA-50
-18.10%
View full RAPP technical analysis

RAPP Stock Catalysts

Track RAPP earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 9, 2027
Analyst target
$71.63
News items
0
View RAPP earnings and stock catalysts

RAPP Dividend Analysis

RAPP dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View RAPP dividend history and analysis

RAPP Financial Data

RAPP revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.84
Periods
8
View RAPP financials

RAPP Risk Analysis

RAPP volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.27
Risk score
39/100
1Y volatility
62.34%
View RAPP risk analysis

RAPP Stock News

RAPP stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read RAPP stock news

RAPP vs Biotechnology Peers

Current peer cohort: RAPP · RCUS · REPL · RLAY · RVMD. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
RAPP
Current stock
43/10042/10033/10039/1000.3562.34%Current
RCUS
Arcus Biosciences, Inc.
39/10043/10034/10042/1000.0562.65%RAPP vs RCUS
REPL
Replimune Group, Inc.
60/100—97/10026/1001.3187.93%RAPP vs REPL
RLAY
Relay Therapeutics, Inc.
56/10037/10076/10052/1001.8465.80%RAPP vs RLAY
RVMD
Revolution Medicines, Inc.
55/10039/10073/10059/1001.6968.69%RAPP vs RVMD
Pairwise Compare links: RCUS · REPL · RLAY · RVMDRAPP vs RCUSRAPP vs REPLRAPP vs RLAYRAPP vs RVMDCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a RAPP stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for RAPP: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-8.25
As of Nov 13, 2026
Revenue growth
—
Gross margin
100.00%
Current debt / equity
0.02
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$40.24M
Quarter free cash flow
-$41.63M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
44.91
MACD
-1.59

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
39/100
Beta
1.27
Annual volatility
62.34%
Max drawdown
-57.14%

RAPP Stock FAQ

What is RAPP stock price today?

Rapport Therapeutics, Inc. Common Stock's current stock price is $26.15. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is RAPP bullish or bearish right now?

RAPP's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is RAPP's market cap?

RAPP's market cap is $1.25B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is RAPP's current P/E ratio?

RAPP's current P/E ratio is -8.25 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is RAPP's RSI?

RAPP's 14-day RSI is 44.91 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is RAPP above its 50-day and 200-day moving averages?

RAPP is -18.10% from its 50-day SMA and -26.52% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is RAPP's next earnings date?

RAPP's next earnings date is currently listed as Mar 9, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does RAPP pay a dividend?

RAPP's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.